Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $188,538 | 5 | 95.8% |
| Travel and Lodging | $7,612 | 2 | 3.9% |
| Food and Beverage | $631.50 | 6 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $196,465 | 9 | $0 (2019) |
| Kastle Therapeutics LLC | $316.01 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $196,465 | 9 | Horizon Therapeutics plc ($196,465) |
| 2017 | $316.01 | 4 | Kastle Therapeutics LLC ($316.01) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $12,458.00 | General |
| Category: KRYSTEXXA | ||||||
| 11/28/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $47,120.00 | General |
| Category: KRYSTEXXA | ||||||
| 11/28/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Travel and Lodging | Cash or cash equivalent | $3,573.25 | General |
| Category: KRYSTEXXA | ||||||
| 11/28/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $119.56 | General |
| Category: KRYSTEXXA | ||||||
| 10/24/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $44,640.00 | General |
| Category: KRYSTEXXA | ||||||
| 10/24/2019 | Horizon Therapeutics plc | — | Travel and Lodging | Cash or cash equivalent | $4,038.35 | General |
| 10/24/2019 | Horizon Therapeutics plc | — | Food and Beverage | Cash or cash equivalent | $195.93 | General |
| 09/20/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $32,240.00 | General |
| Category: KRYSTEXXA | ||||||
| 08/31/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $52,080.00 | General |
| Category: KRYSTEXXA | ||||||
| 09/25/2017 | Kastle Therapeutics LLC | KYNAMRO (Drug) | Food and Beverage | Cash or cash equivalent | $62.42 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/25/2017 | Kastle Therapeutics LLC | KYNAMRO (Drug) | Food and Beverage | Cash or cash equivalent | $48.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/19/2017 | Kastle Therapeutics LLC | KYNAMRO (Drug) | Food and Beverage | Cash or cash equivalent | $124.17 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/18/2017 | Kastle Therapeutics LLC | KYNAMRO (Drug) | Food and Beverage | Cash or cash equivalent | $81.29 | General |
| Category: CARDIOVASCULAR | ||||||
About Dr. Stuart Kupfer, M.D
Dr. Stuart Kupfer, M.D is a Pediatric Endocrinology healthcare provider based in Deerfield, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/24/2011. The National Provider Identifier (NPI) number assigned to this provider is 1790068872.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stuart Kupfer, M.D has received a total of $196,781 in payments from pharmaceutical and medical device companies, with $196,465 received in 2019. These payments were reported across 13 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($188,538).
Practice Information
- Specialty Pediatric Endocrinology
- Location Deerfield, IL
- Active Since 09/24/2011
- Last Updated 09/24/2011
- Taxonomy Code 2080P0205X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1790068872
Products in Payments
- KRYSTEXXA (Biological) $192,231
- KYNAMRO (Drug) $316.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.